Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.
Artikel in diesem Bereich werden auf Englisch angezeigt.
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Trade News am 2026-09-30 zum Markt: Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. Primärquelle: Original bei Nasdaq Market Structure (nasdaq.com).